Answers are grounded in this paper and cite their sources.
This study examined the impact of the polyphenols kaempferol, luteolin, astragalin, and tiliroside on glycoforms in HT-29 and DLD-1 colon cancerous cells at concentrations of 80 and 160 μM. qRT-PCR was used to assess the mRNA of the examined factors. For protein determination, Western blotting was used, and the expression of carbohydrate antigens was examined via ELISA. MUC1, ppGalNAcT2, ST6GalNAcT2, C1GalT1, ST3GalT1, FUT3/4 mRNAs, Tn, sialyl Tn, sialyl T, and Fucα1,3-GlcNAc epitopes were inhibited by all examined polyphenols in both cell lines. Cosmc mRNA was inhibited by all compounds in DLD-1 cells and by luteolin, astragalin, and tiliroside in HT-29 cells. Gal-3 mRNA was only unchanged after tiliroside pretreatment in HT-29 cells. Extracellular domains of MUC1 in HT-29 were inhibited by luteolin, astragalin, tiliroside, and kaempferol had no effect on the 135 kDa unit. In DLD-1 cells, kaempferol and astragalin suppressed these MUC1 domains. Luteolin did not influence the 245 kDa subunit, and tiliroside increased the expression of this domain. The C1GalT1 protein was suppressed by luteolin and tiliroside in HT-29 cells and by kaempferol, luteolin, and astragalin in DLD-1. T-antigen expression was inhibited by all compounds in HT-29 cells; in DLD-1, tiliroside had no impact on this antigen. Our findings indicate the potential use of the studied polyphenols as therapeutic agents in colon cancer.
No takes yet. Share an insight, caveat, or question.
Czerwińska et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: